Status:
COMPLETED
Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Janssen Pharmaceutica
Conditions:
Borderline Personality Disorder
Eligibility:
FEMALE
19+ years
Phase:
PHASE4
Brief Summary
The objective of Study A is to evaluate the efficacy of risperidone on the 4 behavioral dimensions of Berderline Personality Disorder (BPD)in an open label trial:mood swings, impulsivity, thing diffic...
Detailed Description
Study A: An open-label, prospective trial of the efficacy and safety of risperidone in the treatment of BPD.The study is 8 weeks in duration, with a screening visit and follow-up visits at the end of ...
Eligibility Criteria
Inclusion
- Diagnosis of BPD
Exclusion
- Any other Axis I diagnosis except dysthymia, PTSD, or generalized anxiety disorder;substance abuse within a month; unstable medical illness.
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00204347
Start Date
July 1 2003
End Date
October 1 2007
Last Update
June 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35205